Advancing therapy in suboptimally controlled basal insulin-treated type 2 diabetes: Clinical outcomes with iGlarLixi versus premix BIAsp 30 in the SoliMix randomized controlled trial
Open accessPublished version of a preprint
The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To directly compare the efficacy and safety of a fixed-ratio combination, of insulin glargine 100 units/mL and the glucagon-like peptide 1 receptor agonist lixisenatide (iGlarLixi), with those of a premix insulin analog, biphasic aspart insulin 30 (30% insulin aspart and 70% insulin aspart protamine) (BIAsp 30) as treatment advancement in type 2 diabetes suboptimally controlled on basal insulin plus oral antihyperglycemic drugs (OADs). RESEARCH DESIGN AND METHODS: In SoliMix, a 26-week, open-label, multicenter study, adults with suboptimally controlled basal insulin–treated type 2 diabetes (HbA1c ≥7.5% and ≤10%) were randomized to once-daily iGlarLixi or twice-daily BIAsp 30. Primary efficacy end points were noninferiority in HbA1c reduction (margin 0.3%) or superiority in body weight change for iGlarLixi versus BIAsp 30. RESULTS: Both primary efficacy end points were met: after 26 weeks, baseline HbA1c (8.6%) was reduced by 1.3% with iGlarLixi and 1.1% with BIAsp 30, meeting noninferiority (least squares [LS] mean difference −0.2% [97.5% CI −0.4, −0.1]; P < 0.001). iGlarLixi was also superior to BIAsp 30 for body weight change (LS mean difference −1.9 kg [95% CI −2.3, −1.4]) and percentage of participants achieving HbA1c <7% without weight gain and HbA1c <7% without weight gain and without hypoglycemia (all P < 0.001). iGlarLixi was also superior versus BIAsp 30 for HbA1c reduction (P < 0.001). Incidence and rates of American Diabetes Association level 1 and 2 hypoglycemia were lower with iGlarLixi versus BIAsp 30. CONCLUSIONS: Once-daily iGlarLixi provided better glycemic control with weight benefit and less hypoglycemia than twice-daily premix BIAsp 30. iGlarLixi is a more efficacious, simpler, and well-tolerated alternative to premix BIAsp 30 in suboptimally controlled type 2 diabetes requiring treatment beyond basal insulin plus OAD therapy. Video 1:
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pharmacokinetic and pharmacodynamic studies of combination GLP-1 RAs and basal insulin analogs have shown an additive effect on BG decreases.1021,1094–1097”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1094]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455 · cited 2×
“With this approach, advancing basal insulin therapy involves four options: 1) adding rapid-acting insulin progressively to an existing basal insulin regimen; 2) multiple daily premix insulin doses (basal and prandial insulin co-formulation); 3) adding a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 R…”
BackgroundMethod9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
6. Glycemic Targets: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s006 · Cited by 847
Peyrot, M., Barnett, A. H., Meneghini, L. F., & Schumm‐Draeger, P. ‐. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03605.x · Cited by 655 · cited 2×
“Each aforementioned treatment option has been shown to improve glycemic control when used to advance therapy from basal insulin but are also associated with specific adverse effects (4-7).”
BackgroundGough, S. C. L., Bode, B., Woo, V., Rodbard, H. W., Linjawi, S., Poulsen, P., Damgaard, L. H., & Buse, J. B. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70174-3 · Cited by 366
Rosenstock, J., Aronson, R., Grunberger, G., Hanefeld, M., Piatti, P., Serusclat, P., Cheng, X., Zhou, T., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0917 · Cited by 272 · cited 3×
“Both have been shown to provide improved glycemic control versus their individual components, along with weight-benefits compared with basal insulin and fewer gastrointestinal AEs compared with their GLP-1 RA component (17-22).”
BackgroundResultSelf-citationAroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1495 · Cited by 260
Self-citationBuse, J. B., Vilsbøll, T., Thurman, J., Blevins, T. C., Langbakke, I. H., Bøttcher, S. G., & Rodbard, H. W. (2014) · Diabetes Care · doi:10.2337/dc14-0785 · Cited by 259 · cited 2×
“Both have been shown to provide improved glycemic control versus their individual components, along with weight-benefits compared with basal insulin and fewer gastrointestinal AEs compared with their GLP-1 RA component (17-22).”
BackgroundLingvay, I., Manghi, F. P., García-Hernández, P., Norwood, P., Lehmann, L., Tarp-Johansen, M. J., Buse, J. B., & for the DUAL V Investigators (2016) · JAMA · doi:10.1001/jama.2016.1252 · Cited by 220 · cited 1×
“4%) (17-22; 28), lower than previously observed in participants initiating GLP-1 RAs alone (18; 20), and very rarely led to treatment discontinuation (0.”
Background
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Jude, E. B., Malecki, M. T., Gomez Huelgas, R., Prazny, M., Snoek, F., Tankova, T., Giugliano, D., & Khunti, K. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01222-2 · Cited by 52
“They also involve a single daily injection, contributing to regimen simplification and a reduction of treatment burden [51, 63].”
BackgroundBala, C. G., Cerghizan, A., Mihai, B. M., Moise, M., & Guja, C. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060852 · Cited by 26
Polonsky, W. H., Giorgino, F., Rosenstock, J., Whitmire, K., Lew, E., Coudert, M., Alvarez, A., Nicholls, C. J., & McCrimmon, R. J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14822 · Cited by 22
“The SoliMix trial was the first randomized head-to-head study to directly compare the efficacy and safety of iGlarLixi with premix insulin BIAsp 30 in adults with suboptimally controlled T2D on basal insulin plus one or two OADs.10 SoliMix showed that iGlarLixi versus BIAsp 30 was associated with greater HbA1c reducti…”
BackgroundMethodResultInfluentialSelf-citationLiu, M. R., Gu, W., Chen, L., Li, Y., Kuang, H., Du, J., Alvarez, A., Lauand, F., Souhami, E., Zhang, J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15724 · Cited by 22
Self-citationMcCrimmon, R. J., CHENG, A. Y. Y., Galstyan, G. R., Djaballah, K., Li, X., Coudert, M., & Frías, J. P. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14844 · Cited by 17
“As iGlarLixi is associated with less weight gain compared with premixed insulin, it could be a suitable option.(6) The results from the TABLE 2 Exploratory analyses of iGlarLixi versus BI + RAI treatment in participants with high baseline HbA1c or ≥65 years of age”
BackgroundResultInfluentialSelf-citationStandards of Care in Diabetes. The position of Diabetes Poland – 2024
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Broncel, M., Budzynski, A. Z., Cyganek, K., Cypryk, K., CYRANKA, K. M., Czupryniak, L., Dzida, G. J., et al. (2024) · Current Topics in Diabetes · doi:10.5114/ctd/183052 · Cited by 33
Lajara, R., Heller, C. G., Pantalone, K. M., Lew, E., Li, X., DEX, T. A., & Kilpatrick, C. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14974 · Cited by 16
“These findings complement those of the SoliMix trial, a 26-week, randomized study that showed better HbA1c reduction, weight benefit and less hypoglycaemia with once-daily iGlarLixi versus twice-daily biphasic aspart in adults with T2D suboptimally controlled on basal insulin.(28) Further, although clinically similar,…”
ResultHassanein, M. M., Malek, R., Sifri, S. A., Sahay, R. K., Büyükbeşe, M. A., Djaballah, K., Melas‐Melt, L., & Shaltout, I. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01642-2 · Cited by 12
Horváth, L., Novodvorský, P., & Haluzík, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16645 · Cited by 10
“46 In summary, smaller studies showed the feasibility of simplifying MDI or pre-mixed insulin regimens to once-daily basal insulin iGlar and Lixi administered separately in PwT2DM.”
InfluentialHaluzík, M., Seufert, J., Guja, C., Bonnemaire, M., Bigot, G., Tournay, M., Kis, J. T., & Freemantle, N. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01375-8 · Cited by 11
“Similarly, in SoliMix, which compared iGlarLixi to a premix insulin analogue, biphasic insulin aspart 30 (BIAsp 30), once-daily iGlarLixi provided better glycaemic control with body weight benefit and less hypoglycaemia than twice-daily premix BIAsp 30 [10].”
MethodSelf-citationHaluzík, M., Taybani, Z. J., Araszkiewicz, A., Cerghizan, A., Mankovsky, B., Zuhdi, A., & Malecki, M. T. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01610-w · Cited by 12
“…have shown improved efficacy of FRCs of BI and GLP-1 RA when compared with other complex insulin regimens. iGlarLixi was found to be non-inferior and statistically superior in terms of change in HbA1c and body weight along with lower hypoglycaemia versus premixed insulin in the SoliMix trial [21].”
BackgroundResultiGlarLixi for type 2 diabetes: a systematic review and meta-analysis
Liu, Y., Li, C., Li, X., Yang, J., Zheng, Y., Li, F., & Wang, X. (2024) · Endocrine · doi:10.1007/s12020-024-03868-3 · Cited by 8
Haluzík, M., Cypryk, K., Alvarez, A., Lauand, F., Bakıner, O., & Lim, S. K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16276 · Cited by 8
“Furthermore, in the Soli-D and SoliMix trials, most hypoglycaemic events were classified as ADA level 1, 10,12 as observed in the current Soli-SWITCH study.”
InfluentialSelf-citationShao, H., Alsaleh, A. J. O., DEX, T. A., Lew, E., & Fonseca, V. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01300-5 · Cited by 10
“630 SoliMix trial [13] Proportion Black 0.”
BackgroundMethodInfluentialHome, P., McCrimmon, R. J., Rosenstock, J., Blüher, M., Pegelow, K., Melas‐Melt, L., Djaballah, K., Giorgino, F., & the SoliMix trial investigators (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14907 · Cited by 7
“Detailed methods for the open-label SoliMix trial and the dose adjustment algorithms for iGlarLixi and BIAsp 30 have been previously described.(21,22) In brief, adults with suboptimally controlled T2D (HbA1c 58–86 mmol/mol [7.”
BackgroundMethodSelf-citationGuja, C., Kis, J. T., Haluzík, M., Bonnemaire, M., Bigot, G., Tournay, M., Freemantle, N., & Seufert, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15027 · Cited by 8
Self-citationCowart, K., & Carris, N. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16502 · Cited by 7
Candido, R., Modugno, M., Larosa, M., Rossi, M. C., Nicolucci, A., Gabellieri, E., & the ENSURE Study Group (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01328-7 · Cited by 8
“On the other hand, the Solimix study showed that intensifying BOT through iGlarLixi versus twice-daily premix insulin was associated with better glycemic control, fewer daily injections, weight benefit, and less hypoglycemia [11, 12].”
BackgroundMcCrimmon, R. J., PALMER, K. D., Alsaleh, A. J. O., Lew, E., & Puttanna, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01267-3 · Cited by 7
“Per the SoliMix study design, self-monitoring blood glucose was assumed to occur once daily for individuals on iGlarLixi and twice daily for those on premix BIAsp 30; all patients were assumed to be also receiving metformin as concurrent oral diabetes therapy [11, 21].”
BackgroundMethodSelf-citationLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Jiang, Y., Liu, R., Xuan, J., Lin, S., Zheng, Q., & Pang, J. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01255-w · Cited by 7
Novodvorský, P., Thieme, L., Laňková, I., Franková, Š., Veselá, A., Záhumenský, E., Edelsberger, T., Löblová, M., Žižka, O., Vytasil, M., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70362 · Cited by 5
Self-citationBolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16616 · Cited by 6
“44 At the end of the study, HbA1c was lower with iGlarLixi (7.3”
InfluentialMalik, R. A., Anderson, J., Russo, G. T., Amani, M. E. A., Adaş, M., Alvarez, A., Lauand, F., Li, X., & Khunti, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16591 · Cited by 5
“In RCTs comprised of people with T2D previously treated with BI + OAD(s), HbA1c decreased significantly from 8.5% at baseline to 6.9% at Week 30 in the LixiLan-L trial and 8.6% at baseline to 7.3% at Week 26 in the SoliMix trial, 21,22 highlighting the importance of titration of iGlarLixi.”
InfluentialSelf-citationVargas‐Uricoechea, H., Frías, J. P., & Vargas-Sierra, H. D. (2023) · The Review of Diabetic Studies · doi:10.1900/rds.2023.19.14 · Cited by 10
“iGlarLixi was also superior to BIAsp 30 for body weight change SoliMix trial, participants with suboptimally controlled BI–treated T2DM were evaluated [26-34].”
MethodTabák, Á. G., Kempler, P., Guja, C., Eldor, R., Haluzík, M., Klupa, T., Παπάνας, Ν., Stoian, A. P., & Mankovsky, B. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01556-z · Cited by 5
“…with a FRC of Gla-100 and lixisenatide iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30; 30% insulin aspart and 70% insulin aspart protamine) showed better glycaemic control with weight benefit and less hypoglycaemia with OD iGlarLixi compared with twice-daily premixed BIAsp 30 [44].”
MethodMalik, R. A., Hwu, C., Jammah, A. A., Arteaga-Díaz, J. M., Djaballah, K., Pilorget, V., Alvarez, A., Vera, C., & Vikulova, O. K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15599 · Cited by 7
“The findings of this study consolidate the findings of the iGlarLixi RCT programme 8 – 10 and other real-world studies of iGlarLixi, 18,19 confirming that improvements in glycaemic control (HbA1c, FPG and PPG) shown in the RCTs also occur in a real-world setting.”
BackgroundMethodResultSelf-citationAntsiferov, M. B., Demidov, N. A. D., Balberova, M. A., Safronova, T. I., Mishra, O. A. M., & Magomedova, S. G. (2022) · Diabetes Mellitus · doi:10.14341/dm12809 · Cited by 7
McCrimmon, R. J., Home, P., CHENG, A. Y. Y., Giorgino, F., Fonseca, V. A., Souhami, E., Alvarez, A., Picard, P., & Rosenstock, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14825 · Cited by 3
“In the SoliMix trial, iGlarLixi resulted in a lower insulin dose at Week 26 versus premixed BIAsp 30, while also demonstrating a statistically superior change in HbA1c over the same time period.(18) This is probably attributable to the complementary modes of action of the basal insulin (iGlar) and short-acting GLP-1RA…”
BackgroundMethodResultSelf-citationGiorgino, F., Taybani, Z. J., CHENG, A. Y. Y., Tebaibia, A., Anaforoğlu, İ., Lauand, F., Servera, S., Li, X., & Fonseca, V. A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112945 · Cited by 3
Haluzík, M., Al‐Sofiani, M. E., CHENG, A. Y. Y., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15811 · Cited by 4
Self-citationShah, V. N., DEX, T. A., Meneghini, L., Rodrigues, A., & Polonsky, W. H. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16251 · Cited by 2
“24 In a subanalysis of the SoliMix study, 25 initiation of iGlarLixi, compared with BIAsp30, was associated with greater improvement in TRIM-D scores, and the GTEE indicated that a greater proportion of both people with T2D and their physicians perceived a complete or marked improvement of diabetes…”
Frechtel, G. D., Sauque‐Reyna, L., Choza‐Romero, R., Anguiano, L., Melas‐Melt, L., & Sañudo‐Maury, M. E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15125 · Cited by 2
“Detailed methods have been previously published.(16,17) In brief, SoliMix (EudraCT: 2017-003370-13) was a 26-week, open-label, multicentre, randomized controlled study comparing once-daily iGlarLixi versus BIAsp 30.”
BackgroundMethodResultInfluentialSelf-citationKwiendacz, H., Nabrdalik, K., Czupryniak, L., Klupa, T., Malecki, M. T., Myśliwiec, M., Strojek, K., & Gumprecht, J. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02567-1 · Cited by 2
“performed a 26-week, open-label, randomized, multicenter study designed to prove the non-inferiority of iGlarLixi in reducing the HbA1c value and its superiority in body weight control compared to a premix insulin injected twice daily [18].”
MethodMunshi, M. N., Ritzel, R. A., Jude, E. B., DEX, T. A., Melas‐Melt, L., & Rosenstock, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15377 · Cited by 2
Self-citationGiorgino, F., Guja, C., Aydın, H., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111604 · Cited by 2
Self-citationSafety and clinical effectiveness of iGlarLixi in people with type 2 diabetes mellitus in Mexico
Rosas-Guzmán, J., Navarro‐Lara, A., Sañudo‐Maury, M. E., Anguiano, L., & Sauque‐Reyna, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16357 · Cited by 2
Self-citationLandgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2023) · Die Diabetologie · doi:10.1007/s11428-023-01047-y · Cited by 2
Yang, W., Guo, X., Lauand, F., Li, L., Fang, H., Du, Q., & Kang, L. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15414 · Cited by 1
“…of iGlarLixi in US and European PwT2D with uncontrolled T2D previously treated with OADs (LixiLan-O), 19 BI plus OADs (LixiLan-L and SoliMix) 20,21 or daily or weekly GLP-1 RA plus OADs (LixiLan-G), 22 as well as in Japanese people with uncontrolled T2D previously on OADs (LixiLan JP-O1 and…”
MethodGu, W., Wu, X., Zhang, M., Wang, X., Du, Q., Kang, L., Lauand, F., Alvarez, A., & Mu, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70181 · Cited by 1
“20 In an exploratory analysis of the global LixiLan-G study, the glycaemic efficacy and safety of iGlarLixi remained consistent regardless of β -cell function (measured by C-peptide levels) or T2D duration, 21 indicating that iGlarLixi may be a valuable therapeutic option in those with progressive…”
Self-citationYu, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70192 · Cited by 1
“In Phase 3 trials conducted in Asia, 27,28,32,35 iGlarLixi produced greater HbA1c reductions than insulin Glargine or lixisenatide as monothera-pies.”
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Die Diabetologie · doi:10.1007/s11428-023-01144-y · Cited by 1
Yang, N., Lv, L., Han, S.-M., He, L., Li, Z., Yang, Y.-C., Fan, P., Xu, L., Li, W., Zhang, H., et al. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i1.95209 · Cited by 1
Home, P. D., Lauand, F., Djaballah, K., Li, X., Hafidh, K., Mehta, R., Faraoun, K., Anaforoğlu, İ., Serafini, P. R., & Pourrahmat, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16360 · Cited by 1
“10,11 In addition, PPG was measured using a standardized meal test in Aroda et al. 7 and was not assessed in Rosenstock et al. 9 In the IDegAsp trials, PPG was self-measured.”
InfluentialYale, J., de Climens, A. R., Aggarwal, N., DEX, T. A., Gerstein, H. C., Harris, S. B., HRAMIAK, I. M., Stewart, J. A., & Leiter, L. A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01353-6
“basal insulin, iGlarLixi can provide a simpler treatment option compared with complex insulin regimens [9], but the ease of transition from basal insulin to iGlarLixi has not been investigated.”
BackgroundONWARDS and upwards for basal insulin
McCrimmon, R. J. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00825-5
Self-citationRisović, I., Djekic, D., Bojić, M., Markovic, A., Dojčinović, T., Vlatković, V., & Dobrovoljski, D. (2023) · Research Square · doi:10.21203/rs.3.rs-3340824/v1
Yanovskaya, E. A., & Яновская, М. Е. (2023) · FOCUS Endocrinology · doi:10.15829/2713-0177-2023-3-13
De-intensification as a new trend in the treatment of type 2
Yanovskaya, E. A., Яновская, М. Е., & Kaletnik, E. I. (2024) · FOCUS Endocrinology · doi:10.62751/2713-0177-2024-5-2-15 · Cited by 1
Vikulova, O. K., Atanesyan, R. A., Мовсесян, С. Д., Касаткина, Ю. П., Перевязка, А. А., Zaitseva, E. L., Kharakhulakh, M. I., Andreeva, N. V., Krivosheyeva, I. A., Vorobyev, S. V., et al. (2024) · Diabetes Mellitus · doi:10.14341/dm13236 · Cited by 1
Jeter, A. F., Melton, B. L., & Newell, B. J. (2025) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2025.97
Мисникова, И. В., Kovaleva, Y. A., & Andropova, M. A. (2024) · Almanac of Clinical Medicine · doi:10.18786/2072-0505-2024-52-044
Hassanein, M. M., Alessa, T., Hafidh, K., Alzubaidi, L. M. Y., Jallo, M. K. I., Slail, F. Y. A., Elbadawi, H., & Malik, R. A. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01824-6
“There was a larger reduction in HbA1c levels and body weight, lower hypoglycemia events and improvement in overall treatment-related satisfaction [60, 61].”
Huang, C., Yang, S. N., Cheng, C.-P., Lin, C., Lee, Y. S., & Chen, H.-S. (2026) · Diabetic Medicine · doi:10.1111/dme.70275
“21,22 26 Taken together, these results suggest that iGlarLixi may be a safe and well-tolerated alternative to premixed insulin, especially for individuals at elevated hypoglycaemia risk.”
Assaad-Khalil, S. H., Abdelaaty, T., Rizk, M. N., Megallaa, M. H. Z., Elsayed, M., Wafa, A. M., Ismail, A., Sharafeldeen, B., & Amin, N. G. (2026) · Diabetology · doi:10.3390/diabetology7050090
“%) among patients with uncontrolled T2DM, and the percentage of patients achieving HbA1c < 7% without weight gain or hypoglycemia (all p < 0.001) [51].”
InfluentialUrhan, E. (2026) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.1840385
Arteaga-Díaz, J. M., Torres-Grajales, J. L., Sauque‐Reyna, L., Salamanca‐Carrillo, C., & Anguiano, L. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71018
Self-citationZhang, S., Gu, Y., Cheng, Y., Hu, Y., Li, B., Alvarez, A., Lauand, F., Melas‐Melt, L., Zhang, M., Jiang, Y., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71057 · Cited by 1
“…of the SoliMix study of iGlarLixi versus premixed biphasic insulin aspart 30/70 (BIAsp30) also showed consistent benefits with iGlarLixi across participant subgroups defined by baseline age, T2D duration and HbA1c, as well as daily basal insulin dose, body mass index and renal function [16, 17].”
Self-citationTaybani, Z. J., Bótyik, B., Major, D., Fehértemplomi, K., Veres, A., Zatykó, M., Fazekas‐Pongor, V., Panykó, I., Kézdi, Á., Várkonyi, T. T., et al. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1906632
Mahmood, T., Myrtziou, I., & Kanakis, I. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02089-x
“Fourteen trials involving 6,717 participants con - tributed to the meta-analysis of participants experiencing Included RCTs: [ 13 – [16 ], 26– [ 37, 39 ] at least one trial-defined hypoglycaemic event [ 13 –16 , 26 , 28 –30 , 32, 34 – 38].”
Influential(2026) · ADA Clinical Compendia · doi:10.2337/db20261-33
Giorgino, F., Haluzík, M., Alvarez, A., Lauand, F., Assaad-Khalil, S. H., Thacker, H. P., Klupa, T., Deyneli, O., & Rosenstock, J. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71436
Self-citation
Metadata
- Authors
- Rosenstock, J., Emral, R., Sauque-Reyna, L., Mohan, V., Trescolí, C., Al Sifri, S., Lalic, N., Alvarez, A., Picard, P., Bonnemaire, M., Demil, N., & McCrimmon, R. J.
- Affiliations
- Dallas Diabetes Research Center (US)
- Department of Endocrinology and Metabolic Diseases, Ankara University Faculty of Medicine, Ankara, Turkey
- Instituto de Diabetes Obesidad y Nutrición S.C., Cuernavaca, Morelos, Mexico
- Madras Diabetes Research Foundation (IN)
- Hospital de La Ribera (ES)
- Al Hada Military Hospital, Taif, Saudi Arabia
- University of Belgrade (RS)
- Sanofi (Argentina) (AR)
- IviData LIFE SCIENCES, Levallois-Perret, France
- Sanofi (France) (FR)
- University of Dundee (GB)
- Corresponding author
- Rosenstock, Julio
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2021-08-06
- Volume
- 44
- Issue
- 10
- Pages
- 2361-2370
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC8740944
- OpenAlex
- W3176298177
- Cited by
- 63
- References
- 27
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 16 · 2023: 12 · 2022: 12
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Sanofi
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, basal insulin, iGlarLixi, lixisenatide, insulin glargine, biphasic insulin aspart, premixed insulin, GLP-1 receptor agonists, glycemic control, HbA1c reduction, weight change, hypoglycemia, suboptimal glycemic control, oral antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.